SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc., (OTCBB:AEMD) announced today that it has received approval to initiate clinical testing of the Hemopurifier® in human studies to be conducted at the Fortis Hospital (www.fortishealthcare.com) in Delhi, India. The study, approved by the Ethics Committee for Research at Fortis Hospital, will evaluate safety of the HemopurifierÆ in up to ten patients with end-stage renal disease. Pending patient accrual, the study is expected to begin in August. Dr. Vijay Kher, Director of Nephrology at Fortis has agreed to be the principal investigator of the study. Previously, Dr. Kher acted as principal investigator of a Hemopurifier® study conducted at the Apollo Hospital in Delhi. The Apollo study documented initial safety of the Hemopurifier®, and provided early efficacy observations during 24-treatments administered to health compromised dialysis patients co-infected with Hepatitis-C (HCV).
